Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Accumulated Depreciation: 2019-2022

Historic Accumulated Depreciation for Avidity Biosciences (RNA) over the last 3 years, with Sep 2022 value amounting to $2.7 million.

  • Avidity Biosciences' Accumulated Depreciation rose 38.54% to $2.7 million in Q3 2022 from the same period last year, while for Sep 2022 it was $2.7 million, marking a year-over-year increase of 38.54%. This contributed to the annual value of $1.7 million for FY2021, which is 12.43% down from last year.
  • Per Avidity Biosciences' latest filing, its Accumulated Depreciation stood at $2.7 million for Q3 2022, which was up 15.62% from $2.4 million recorded in Q2 2022.
  • Avidity Biosciences' Accumulated Depreciation's 5-year high stood at $2.7 million during Q3 2022, with a 5-year trough of $1.6 million in Q4 2019.
  • In the last 3 years, Avidity Biosciences' Accumulated Depreciation had a median value of $1.9 million in 2020 and averaged $2.0 million.
  • As far as peak fluctuations go, Avidity Biosciences' Accumulated Depreciation fell by 12.43% in 2021, and later soared by 38.54% in 2022.
  • Over the past 4 years, Avidity Biosciences' Accumulated Depreciation (Quarterly) stood at $1.6 million in 2019, then climbed by 20.45% to $2.0 million in 2020, then decreased by 12.43% to $1.7 million in 2021, then soared by 38.54% to $2.7 million in 2022.
  • Its Accumulated Depreciation stands at $2.7 million for Q3 2022, versus $2.4 million for Q2 2022 and $2.0 million for Q1 2022.